|
1
|
Liebner DA and Shah MH: Thyroid cancer:
Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab.
2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Catalano MG, Poli R, Pugliese M, Fortunati
N and Boccuzzi G: Emerging molecular therapies of advanced thyroid
cancer. Mol Aspects Med. 31:215–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu S, Semenciw R, Ugnat AM and Mao Y:
Increasing thyroid cancer incidence in Canada, 1970–1996: Time
trends and age-period-cohort effects. Br J Cancer. 85:1335–1339.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toniato A, Boschin I, Casara D, Mazzarotto
R, Rubello D and Pelizzo M: Papillary thyroid carcinoma: Factors
influencing recurrence and survival. Ann Surg Oncol. 15:1518–1522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galasso M, Sandhu SK and Volinia S:
MicroRNA expression signatures in solid malignancies. Cancer J.
18:238–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y and Srivastava D: A developmental
view of microRNA function. Trends Biochem Sci. 32:189–197. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anfossi S, Fu X, Nagvekar R and Calin GA:
MicroRNAs, regulatory messengers inside and outside cancer cells.
Adv Exp Med Biol 1056. 87–108. 2018. View Article : Google Scholar
|
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tie J and Fan D: Big roles of microRNAs in
tumorigenesis and tumor development. Histol Histopathol.
26:1353–1361. 2011.PubMed/NCBI
|
|
14
|
Li R, Dong B, Wang Z, Jiang T and Chen G:
MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by
targeting ROCK1. Biomed Pharmacother. 102:988–995. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang R, Ma Q, Ji L, Yao Y, Ma M and Wen Q:
miR-622 suppresses tumor formation by directly targeting VEGFA in
papillary thyroid carcinoma. Onco Targets Ther. 11:1501–1509. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang L, Kong D and Xu W: MicroRNA-625-3p
promotes the proliferation, migration and invasion of thyroid
cancer cells by up-regulating astrocyte elevated gene 1. Biomed
Pharmacother. 102:203–211. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen J and Li M: MicroRNA-744 inhibits
cellular proliferation and invasion of colorectal cancer by
directly targeting oncogene Notch1. Oncol Res. Feb 22–2018.(Epub
ahead of print). View Article : Google Scholar
|
|
18
|
Chen XF and Liu Y: MicroRNA-744 inhibited
cervical cancer growth and progression through apoptosis induction
by regulating Bcl-2. Biomed Pharmacother. 81:379–387. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT,
Guo W, Liu J, Li JS, Jie-Yin, Zang YJ and Zhang ZT: miR-744 is a
potential prognostic marker in patients with hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 39:359–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin S, Meng W, Zhang W, Liu J, Wang P, Xue
S and Chen G: Expression of the NOB1 gene and its clinical
significance in papillary thyroid carcinoma. J Int Med Res.
41:568–572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu J, Dong BF, Wang PS, Ren PY, Xue S,
Zhang XN, Han Z and Chen G: Silencing NOB1 enhances doxorubicin
antitumor activity of the papillary thyroid carcinoma in vitro and
in vivo. Oncol Rep. 33:1551–1559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng W, Wang PS, Liu J, Xue S, Wang GM,
Meng XY and Chen G: Adenovirus-mediated siRNA targeting NOB1
inhibits tumor growth and enhances radiosensitivity of human
papillary thyroid carcinoma in vitro and in vivo. Oncol Rep.
32:2411–2420. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JC, Gundara JS, Glover A, Serpell J
and Sidhu SB: MicroRNA expression profiles in the management of
papillary thyroid cancer. Oncologist. 19:1141–1147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chruscik A and Lam AK: Clinical
pathological impacts of microRNAs in papillary thyroid carcinoma: A
crucial review. Exp Mol Pathol. 99:393–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyamae M, Komatsu S, Ichikawa D,
Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H,
Shiozaki A, et al: Plasma microRNA profiles: Identification of
miR-744 as a novel diagnostic and prognostic biomarker in
pancreatic cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang
C, Yan H and Liu T: MiR-744 increases tumorigenicity of pancreatic
cancer by activating Wnt/β-catenin pathway. Oncotarget.
6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guan H, Liu C, Fang F, Huang Y, Tao T,
Ling Z, You Z, Han X, Chen S, Xu B and Chen M: MicroRNA-744
promotes prostate cancer progression through aberrantly activating
Wnt/β-catenin signaling. Oncotarget. 8:14693–14707. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei
WI, Ho WK and Wong TS: MicroRNA 744-3p promotes MMP-9-mediated
metastasis by simultaneously suppressing PDCD4 and PTEN in
laryngeal squamous cell carcinoma. Oncotarget. 7:58218–58233.
2016.PubMed/NCBI
|
|
30
|
Yu Q, Zhang F, Du Z and Xiang Y:
Up-regulation of serum miR-744 predicts poor prognosis in patients
with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302.
2015.PubMed/NCBI
|
|
31
|
Lin F, Ding R, Zheng S, Xing D, Hong W,
Zhou Z and Shen J: Decrease expression of microRNA-744 promotes
cell proliferation by targeting c-Myc in human hepatocellular
carcinoma. Cancer Cell Int. 14:582014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang Y, Zhu X, Wang J, Li N, Li D, Sakib
N, Sha Z and Song W: MiR-744 functions as a proto-oncogene in
nasopharyngeal carcinoma progression and metastasis via
transcriptional control of ARHGAP5. Oncotarget. 6:13164–13175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tone Y, Tanahashi N, Tanaka K, Fujimuro M,
Yokosawa H and Toh e-A: Nob1p, a new essential protein, associates
with the 26S proteasome of growing saccharomyces cerevisiae cells.
Gene. 243:37–45. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wyler E, Zimmermann M, Widmann B, Gstaiger
M, Pfannstiel J, Kutay U and Zemp I: Tandem affinity purification
combined with inducible shRNA expression as a tool to study the
maturation of macromolecular assemblies. RNA. 17:189–200. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luo L, Wang Y, Yin Y, Ge J and Lu X:
Effects of NOB1 on the pathogenesis of osteosarcoma and its
expression on the chemosensitivity to cisplatin. Oncol Lett.
15:3548–3551. 2018.PubMed/NCBI
|
|
37
|
Kong R, Liu W, Guo Y, Feng J, Cheng C,
Zhang X, Ma Y, Li S, Jiang J, Zhang J, et al: Inhibition of NOB1 by
microRNA-330-5p overexpression represses cell growth of non-small
cell lung cancer. Oncol Rep. 38:2572–2580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin Y, Xu T, Teng H and Cui M: Anticancer
activity of NOB1-targeted shRNA combination with TRAIL in
epithelial ovarian cancer cells. Int J Clin Exp Pathol.
8:10061–10071. 2015.PubMed/NCBI
|
|
39
|
He XW, Feng T, Yin QL, Jian YW and Liu T:
NOB1 is essential for the survival of RKO colorectal cancer cells.
World J Gastroenterol. 21:868–877. 2015. View Article : Google Scholar : PubMed/NCBI
|
